Globe Newswire

August 1, 2024

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

Outpace in the Press

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

March 21, 2021

In The News

Endpoints News

A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground

DOWNLOAD

News

All

November 7, 2022

Publications

Society for Immunotherapy of Cancer (SITC)

Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity

Publications

October 11, 2022

Publications

Frontiers in Molecular Medicine

Safety switch optimization enhances antibody-mediated elimination of CAR T cells

Publications

June 28, 2022

In The News

GeekWire

Biotech startups join AWS and other partners in open-source project to help design new proteins

News

February 21, 2022

In The News

Fred Hutch Cancer Center

Red Light, Green Light: Precise cell targeting with Co-LOCKR

News

October 6, 2021

In The News

Business Insider

Power players: These 12 young serial founders are building the next generation of biotech startups

News

May 18, 2021

In The News

BioCentury

Lyell spinout Outpace leverages de novo proteins to control cell and gene therapies

News

August 1, 2024

In The News

Endpoints News

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

News

August 1, 2024

In The News

synbiobeta

AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding

News

August 1, 2024

In The News

GeekWire

Protein design startup Outpace lands $144M to test treatments that target solid tumors

News

August 2, 2023

In The News

GeekWire

Seattle startups move into growing science cluster in South Lake Union

News

July 10, 2023

In The News

GeekWire

How AI is changing the way scientists engineer drugs, biosensors, enzymes and more

News

May 26, 2023

In The News

Endpoints News

Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle

News

November 5, 2024

Public Relations

Globe Newswire

Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR

August 1, 2024

Public Relations

Globe Newswire

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

PR

April 4, 2024

Public Relations

Globe Newswire

Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting

PR

October 31, 2023

Public Relations

Globe Newswire

Outpace Bio to present new data on tumor-restricted IL-12 designed leveraging OutSmart technology to enhance solid tumor T cell therapies at SITC 2023

PR

May 22, 2023

Public Relations

Globe Newswire

Outpace Bio expands Seattle presence with cell therapy research hub & collaborations with leading experts in protein design & cancer immunotherapy

PR

May 18, 2023

Public Relations

Globe Newswire

Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)

PR

August 1, 2023

Publications

American Society for Gene & Cell Therapy (ASGCT)

OutSmart™ IL-2/15 Safely Stimulates CAR T Proliferation and Persistence in the Tumor while Limiting Regulatory T Cell Activation

Publications

May 18, 2023

Publications

American Society for Gene & Cell Therapy (ASGCT)

OutSmart™ IL-2/15: A CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity

Publications

November 7, 2022

Publications

Society for Immunotherapy of Cancer (SITC)

Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity

Publications

October 11, 2022

Publications

Frontiers in Molecular Medicine

Safety switch optimization enhances antibody-mediated elimination of CAR T cells

Publications

Press Kit

The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.

Download

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

Outpace in the Press

Press Kit

Connect With Us